Phase 2 N=41 A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Dose Escalation: Solid Tumors · MTD: Soft Tissue Sarcomas
Primary: Maximum Tolerated Dose (MTD) PXD101 — 1000 mg/m²
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Congenital Bleeding Disorder · Haemophilia A · Haemophilia B
Primary: Number of Adverse Events (AEs) — 10; 8; 5; 5 events
N/A N=67 A Study of a Novel Silicone Dressing to Minimize Scar Formation
Hypertrophic
Primary: Visual Analogue Scale (VAS) — 2.90; 3.29 score on a scale
Phase 3 N=14 A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021
Short Bowel Syndrome
Primary: Summary of Treatment-emergent Adverse Events — 4; 5 participants
Phase 2 N=20 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-negative Breast Cancer · Progesterone Receptor-positive Breast Cancer
Primary: Best Overall Response — 5; 2 patients with progressive disease
Phase 2 N=45 Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers
Hyperglycemia
Primary: Change in Insulin Basal Level — -24.37; -29.60 pmol/L — p=<0.001
Phase 1 N=30 Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) for Simvastatin — 38.142; 26.601 ng*h/ml
N/A N=1,007 Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Chemotherapy-induced Febrile Neutropenia
Primary: Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia — 73.4; 88.3; 41.1; 25.0 percentage of investigators
Phase 1 N=30 Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Midazolam — 103.348; 120.1 ng*hr/mL
Phase 2 N=21 Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis
Psoriasis
Primary: Mean Change From Baseline to Day 28 in PSS (Psoriasis Severity Score) of the Treatment Target Lesions Compared to Placebo Target Lesions — -1.9; -1.5 PSS score
Phase 1 N=9 The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions — 112,236.7; 154,676.6 ng*hr/mL
Early Phase 1 N=131 Managing Chronic Pain in Veterans With Substance Use Disorders
Chronic Pain
Primary: Pain Intensity, as Measured by Average Pain Within the Last Week (NRS-1) — 5.82; 6.47 units on a scale — p=<0.05
Phase 3 N=60 Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment — -18.07; -103.56; -122.94 mg*h/dL…
N/A N=27 SR-WBV Training for Frail Elderly in the Skilling up Stage
Poor Performance Status · Muscle Weakness
Primary: Physical Functional Performance — 3; 4; 6; 4 units on a scale — p=< 0.05
N/A N=24 Balance Training vs. Balance Training w/ STARS
Ankle (Ligaments); Instability (Old Injury)
Primary: Balance — 68.7; 66.2; 87.7; 85.5 % of leg length — p=.904